5JD0.F ExpreS2ion Biotech Holding AB (publ)
- Market cap
- EUR 2.19M
- P/E
- -
- P/B
- 0.55x
- ROE
- -92.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5JD0.F undervalued?
Graham numberThe Graham number of ExpreS2ion Biotech Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ExpreS2ion Biotech Holding AB (publ) fundamental analysis
No fundamental analysis for ExpreS2ion Biotech Holding AB (publ) yet.
ExpreS2ion Biotech Holding AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-e…
Full company profileExpreS2ion Biotech Holding AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ExpreS2ion Biotech Holding AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 12.2M | 5.09M | 7.05M | 3.01M | 3.66M | 6.10M |
| Gross Profit | 4.72M | 5.00K | 3.40M | -2.67M | 137K | 2.46M |
| Operating Income | -48.4M | -128M | -106M | -67.7M | -44.3M | -47.8M |
| EBITDA | - | -124M | -97.9M | -42.2M | -42.3M | -46.7M |
| Net Income | -43.9M | -119M | -91.4M | -36.0M | -38.1M | -38.6M |
| EPS | -42 | -100 | -61 | -14 | -3.85 | -1.62 |
| Balance Sheet | ||||||
| Total Assets | 152M | 137M | 78.7M | 105M | 65.1M | 57.8M |
| Total Liabilities | 11.6M | 34.0M | 13.3M | 40.1M | 29.4M | 16.0M |
| Shareholders' Equity | 140M | 103M | 65.4M | 64.8M | 35.7M | 41.8M |
| Cash & Short-term Investments | 37.1M | 111M | 57.6M | 81.5M | 47.6M | 34.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -45.6M | -99.6M | -101M | -33.9M | -40.9M | -76.0M |
| Capital Expenditure | 715K | 383K | 2.02M | 870K | 0.00 | 614K |
| Free Cash Flow | -46.4M | -100.0M | -103M | -34.8M | -40.9M | -76.6M |
| Ratios | ||||||
| ROE | -31.3% | -114.8% | -139.8% | -55.6% | -106.7% | -92.4% |
| ROA | -28.9% | -86.3% | -116.2% | -34.4% | -58.5% | -66.8% |
| Net Profit Margin | -359.0% | -2,332.0% | -1,296.5% | -1,196.1% | -1,041.4% | -632.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ExpreS2ion Biotech Holding AB (publ) dividends
ExpreS2ion Biotech Holding AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:40 on Oct 30, 2024.
Who owns ExpreS2ion Biotech Holding AB (publ)
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 39.5M
- Free float 23.2M
ExpreS2ion Biotech Holding AB (publ) company profile
- Company name
- ExpreS2ion Biotech Holding AB (publ)
- Ticker
- 5JD0.F
- ISIN
- SE0023261292
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- Rönnowsgatan 8c, Helsingborg, Sweden, 252 25
- Website
- expres2ionbio.com
About ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
ExpreS2ion Biotech Holding AB (publ) management
3- Mr. Bent U. Frandsen MScChief Executive Officer
- Mr. Keith AlexanderChief Financial Officer
- Dr. Max M. SogaardChief Scientific Officer